The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.

In an analysis of 1,034 fit adults aged 70 years and younger, age and genetic features were identified as the factors most ...

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform do ...

Researchers from Karl Landsteiner University of Health Sciences (KL Krems) have discovered that combining two existing drugs ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...